VOLPINI, Rosaria
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 22.016
EU - Europa 9.224
AS - Asia 7.165
SA - Sud America 1.007
Continente sconosciuto - Info sul continente non disponibili 540
AF - Africa 266
OC - Oceania 16
Totale 40.234
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 21.247
CN - Cina 2.917
SG - Singapore 2.178
RU - Federazione Russa 1.964
IT - Italia 1.603
PL - Polonia 1.552
DE - Germania 979
BR - Brasile 831
GB - Regno Unito 661
CA - Canada 578
HK - Hong Kong 573
UA - Ucraina 540
FR - Francia 528
SE - Svezia 527
VN - Vietnam 487
FI - Finlandia 365
KR - Corea 230
TR - Turchia 219
ZA - Sudafrica 182
IE - Irlanda 139
IN - India 121
JP - Giappone 104
NL - Olanda 73
MX - Messico 68
AR - Argentina 57
ES - Italia 53
BD - Bangladesh 50
BE - Belgio 49
EU - Europa 49
CZ - Repubblica Ceca 37
IQ - Iraq 36
IR - Iran 33
EC - Ecuador 30
AT - Austria 28
PK - Pakistan 26
CO - Colombia 25
VE - Venezuela 23
CR - Costa Rica 20
ID - Indonesia 20
RO - Romania 18
UZ - Uzbekistan 18
AE - Emirati Arabi Uniti 17
GT - Guatemala 17
IL - Israele 17
TW - Taiwan 17
CH - Svizzera 16
LT - Lituania 16
SA - Arabia Saudita 16
KE - Kenya 15
HN - Honduras 14
JM - Giamaica 14
CL - Cile 13
SV - El Salvador 13
TN - Tunisia 13
TT - Trinidad e Tobago 13
JO - Giordania 12
PY - Paraguay 12
AU - Australia 11
CW - ???statistics.table.value.countryCode.CW??? 11
MA - Marocco 11
RS - Serbia 11
EG - Egitto 10
AZ - Azerbaigian 9
DZ - Algeria 9
PE - Perù 9
PH - Filippine 9
EE - Estonia 8
NP - Nepal 8
DK - Danimarca 7
LB - Libano 7
NI - Nicaragua 7
AM - Armenia 6
BG - Bulgaria 6
GP - Guadalupe 6
MY - Malesia 6
TH - Thailandia 6
CI - Costa d'Avorio 5
GR - Grecia 5
HR - Croazia 5
LV - Lettonia 5
PA - Panama 5
PR - Porto Rico 5
SC - Seychelles 5
AL - Albania 4
BO - Bolivia 4
GE - Georgia 4
KZ - Kazakistan 4
NZ - Nuova Zelanda 4
PT - Portogallo 4
BB - Barbados 3
BY - Bielorussia 3
DO - Repubblica Dominicana 3
ET - Etiopia 3
KH - Cambogia 3
LU - Lussemburgo 3
NO - Norvegia 3
SK - Slovacchia (Repubblica Slovacca) 3
UY - Uruguay 3
BS - Bahamas 2
CM - Camerun 2
Totale 39.720
Salva come PNG Salva come JPEG
Città #
Ashburn 1.933
Fairfield 1.763
Woodbridge 1.494
Warsaw 1.349
Jacksonville 1.328
San Jose 1.128
Singapore 1.090
Houston 1.073
Chandler 1.053
Council Bluffs 804
Seattle 785
Wilmington 757
Ann Arbor 648
Cambridge 606
Dallas 601
Boardman 567
Hong Kong 540
Beijing 465
Nanjing 463
Toronto 348
New York 289
Los Angeles 286
The Dalles 280
Camerino 252
Seoul 205
San Mateo 199
Columbus 191
Tongling 189
Dearborn 188
Princeton 187
Kraków 185
Lawrence 180
Düsseldorf 175
Helsinki 173
Istanbul 168
Lauterbourg 162
Johannesburg 160
Ogden 147
Ho Chi Minh City 145
Santa Clara 143
Chicago 140
Buffalo 138
Dublin 137
London 130
Lachine 128
Moscow 124
Nanchang 123
Phoenix 116
Hanoi 112
Shanghai 106
Milan 101
São Paulo 99
Guangzhou 97
Shenyang 91
Munich 88
San Diego 88
Tianjin 87
Tokyo 81
Frankfurt am Main 78
Kunming 74
Hebei 62
Rome 62
Jiaxing 56
Orem 54
Washington 50
Brussels 48
Denver 47
Edinburgh 46
St Louis 43
Atlanta 42
Changsha 42
Wuhan 40
Jinan 39
Redwood City 39
Ningbo 38
Centro 37
Hangzhou 37
San Francisco 37
Philadelphia 36
Boston 35
Dong Ket 35
Stockholm 35
Manchester 34
Trieste 33
Brooklyn 32
Salt Lake City 32
Montreal 31
Turku 31
Venezia 31
Verona 31
Zhengzhou 30
Poplar 29
Chennai 28
Hefei 28
Mexico City 28
Rio de Janeiro 28
Ascoli Piceno 26
Norwalk 26
Brno 25
Detroit 25
Totale 26.325
Salva come PNG Salva come JPEG
Nome #
1,2,4-Triazolo[1,5-a]quinoxaline derivatives and their simplified analogues as adenosine A3 receptor antagonists. Synthesis, structure–affinity relationships and molecular modeling studies 663
A2AR agonists/A3R antagonists: design, synthesis, and biological evaluation of new ligands with dual activity 468
The Length and Flexibility of the 2-Substituent of 9-Ethyladenine Derivatives Modulate Affinity and Selectivity for the Human A2A Adenosine Receptor 427
Overview on Radiolabel-Free in Vitro Assays for GPCRs 418
Pharmacological characterization of the GPR17 receptor dual profile 413
GPR17 receptor modulators and their therapeutic implications: review of recent patents 413
The G Protein-Coupled Receptor GPR17: Overview and Update 398
The 1,2,4-Triazolo[4,3-a]pyrazin-3-one as a Versatile Scaffold for the Design of Potent Adenosine Human Receptor Antagonists. Structural Investigations to Target the A2A Receptor Subtype 397
Update on novel purinergic P2X3 and P2X2/3 receptor antagonists and their potential therapeutic applications 393
2′,3′-O-Substituted ATP derivatives as potent antagonists of purinergic P2X3 receptors and potential analgesic agents 375
2’,3’-O-Substituted ATP derivatives as potent antagonists of purinergic P2X3 receptors and potential analgesic agents 370
Medicinal chemistry and pharmacology of A2B adenosine receptors 318
Synthesis and antitumor evaluation of bis aza-anthracene-9,10-diones and bis aza-anthrapyrazole-6-ones 309
Adenine based acyclic-nucleotides as novel P2X3 receptor ligands 307
8-(2-Furyl)adenine derivatives as A2A adenosine receptor ligands 306
Dual target strategy: Combining distinct non-dopaminergic treatments reduces neuronal cell loss and synergistically modulates l -DOPA-induced rotational behavior in a rodent model of Parkinson's disease 302
Neuroprotective potential of adenosine A1 receptor partial agonists in experimental models of cerebral ischemia 301
Neuropeptide S Receptor: recent updates on non-peptide antagonist discovery 298
Medicinal Chemistry of P2X Receptors: Agonists and Orthosteric Antagonists 291
2-Aralkynyl and 2-Heteroalkynyl derivatives of Adenosine-5'-N-ethyluronamide as selective A2a adenosine receptor agonists 284
Levels of polychlorinated biphenyls in fish and shellfish from the Adriatic Sea 281
Investigation on 2′,3′-O-Substituted ATP Derivatives and Analogs as Novel P2X3 Receptor Antagonists 278
Simulation and Comparative Analysis of Different Binding Modes of Non-nucleoside Agonists at the A2A Adenosine Receptor 278
2-Substituted N-ethylcarboxamidoadenosine derivatives as high affinity agonists at human A(3) adenosine receptors 272
Approaches for designing and discovering purinergic drugs for gastrointestinal diseases 269
Ex-vivo absorption study of lysine R-lipoate salt, a new pharmaceutical form of R-ALA 268
2-Alkynyl derivatives of Adenosine-5'-N-ethyluronamide (NECA): selective A2 adenosine receptor agonists with potent inhibitory activity on Platelet aggregation 267
2-Alkynyl derivatives of adenosine and adenosine-5'-N-ethyluronamide as selective agonists at A2 adenosine receptors 267
3'-Deoxyribofuranose derivatives of 1-deaza and 3-deaza adenosine and their activity as adenosine deaminase inhibitors 266
A(2A) adenosine receptor agonists reduce both high-palatability and low-palatability food intake in female rats 260
Adenine and deazaadenine nucleoside and deoxynucleoside analogues: inhibition of viral replication of sheep MVV (in vitro model for HIV) and bovine BHV-1 260
Antioxidant-conjugated 1,2,4-Triazolo[4,3-a]pyrazin-3-one Derivatives: Highly Potent and Selective Human A2A Adenosine Receptor Antagonists Possessing Protective Efficacy in Neuropathic Pain 259
9-ethyladenine derivatives as adenosine receptor antagonists: 2- and 8-substitution results in distinct selectivities 257
Determination of ink photoinitiators in packaged beverages by gas chromatography-mass spectrometry and liquid chromatography-mass spectrometry 257
Biomarkers mapping of neuropathic pain in a nerve chronic constriction injury mice model 257
Human cytidine deaminase: understanding the catalytic mechanism 252
Purinergic P2X receptors: Structural models and analysis of ligand-target interaction 250
Human placenta cytidine deaminase: a zinc metalloprotein 249
New substituted 9-propyladenine derivatives as A2Aadenosine receptor antagonists 249
8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A(2A) and A(2B) receptors ligands 249
Non-Nucleoside Agonists of the Adenosine Receptors: An Overview 249
Isoenzymatic forms of human cytidine deaminase 248
Design, synthesis, and biological evaluation of new mitonafide derivatives as potential antitumor drugs 246
A(2A) Adenosine receptor and its modulators: overview on a druggable GPCR and on structure-activity relationship analysis and binding requirements of agonists and antagonists 242
Innovative functional cAMP assay for studying G protein-coupled receptors: application to the pharmacological characterization of GPR17 242
Antiviral properties of deazaadenine nucleoside derivatives 242
Purine and deazapurine nucleosides: synthetic approaches, molecular modeling and biological activity 240
“Third Joint Italian-German Purine Club Meeting - Purinergic Receptors: New Frontiers for Novel Therapies” 240
New sensible method to quantize the intestinal absorption of receptor ligands 237
2-Alkenyl and 2-alkyl derivatives of adenosine and adenosine-5'-N-ethyluronamide: different affinity and selectivity of E- and Z-diastereomers at A2A adenosine receptors 235
2- And 8- alkynyladenosines: conformational studies and docking to human adenosine A(3) receptor can explain their different biological behavior 234
Adenosine deaminase inhibitors: synthesis and structure-activity relationships of 2-hydroxy-3-nonyl derivatives of azoles 234
"N-Cycloalkylalkyl derivatives of adenosine and 1-deazaadenosine as agonists and partial agonists at the A1 adenosine receptor 233
Adenosine A(2A) receptor antagonists: new 8-substituted 9-ethyladenines as tools for in vivo rat models of Parkinson's disease 233
Molecular modeling studies on the human neuropeptide S receptor and its antagonists. 233
Exploring the 7-oxo-thiazolo[5,4-d]pyrimidine core for the design of new human adenosine A3 receptor antagonists. Synthesis, molecular modeling studies and pharmacological evaluation 233
Adenosine deaminase: Functional implications and different classes of inhibitors 232
Molecular modeling study on potent and selective adenosine A3 receptor agonists. 232
Evidence for the existence of a specific G protein-coupled receptor activated by guanosine 231
A3 Adenosine Receptor Antagonists with Nucleoside Structures and Their Anticancer Activity 227
Comparison and optimization of transient transfection methods at human astrocytoma cell line 1321N1 225
Antiviral activity of purine nucleoside analogs against bovine herpesvirus (BHV-1) and maedi visna virus (MVV) 225
Novel human adenosine receptor antagonists based on the 7-amino-thiazolo[5,4-d]pyrimidine scaffold. Structural investigations at the 2-, 5- and 7-positions to enhance affinity and tune selectivity 225
CX3CL1-induced modulation at CA1 synapses reveals multiple mechanisms of EPSC modulation involving adenosine receptor subtypes. 224
Adenosine receptor modeling: what does the A2A crystal structure tell us? 222
2- And 8-alkynyl-9-ethyladenines: Synthesis and biological activity at human and rat adenosines receptors 221
Different efficacy of adenosine and NECA derivatives at the human A3 adenosine receptor: Insight into the receptor activation switch 219
Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease 219
2-substituted 5 '-N-methylcarboxamidoadenosine (MECA) derivatives as A(3) adenosine receptor ligands 216
Frontal affinity chromatography-mass spectrometry useful for characterization of new ligands for GPR17 receptor. 216
The importance of alkynyl chain presence for the activity of adenine nucleosides/nucleotides on purinergic receptors 216
Identification of alpha(1)-adrenoceptor subtypes involved in contraction of young CD rat epididymal vas deferens 215
2-phenylhydroxypropynyladenosine derivatives as high potent agonists at A(2B) adenosine receptor subtype 214
Structure-activity relationships of adenine and deazaadenine derivatives as ligands for adenine receptors, a new purinergic receptor family 214
Ring opening reactions: synthesis of AICAR analogs as potential antimetabolite agents 213
Purinergic Ligands as Potential Therapeutic Tools for the Treatment of Inflammation-Related Intestinal Diseases 213
Diazepinone nucleosides as inhibitors of cytidine deaminase 212
Simulation and comparative analysis of binding modes of nucleoside and non-nucleoside agonists at the A2B adenosine receptor 211
Pharmacological postconditioning of the rabbit heart with non-selective, A1, A2A and A3 adenosine receptor agonists 210
Novel 8-amino-1,2,4-triazolo[4,3-a]pyrazin-3-one derivatives as potent human adenosine A1 and A2A receptor antagonists. Evaluation of their protective effect against β-amyloid-induced neurotoxicity in SH-SY5Y cells 210
Unexpected synthesis of acyclic adenine nucleosides 209
2-ChloroATP exerts anti-tumoral actions not mediated by P2 receptors in neuronal and glial cells line 209
Innovative functional cAMP assay: application to the pharmacological characterization of GPR17 208
Human adenosine A3 receptor as selective target of new 2-aralkynyl-N6-methyl-MECA derivatives 206
New 2,6,9-trisubstituted adenines as adenosine receptor antagonists: a preliminary SAR profile 205
Adenosine deaminase inhibitors: structure-activity relationships in 1-deazaadenosine and erythro-9-(2-hydroxy-3-nonyl)adenine analogs 205
[3H]HEMADO – a novel tritiated agonist selective for the human adenosine A(3) receptor 205
Introduction of alkynyl chains on C-8 of adenosine led to very selective antagonists of the A(3) adenosine receptor 203
Synthesis and receptor affinity of polysubstituted adenosines 202
Chemical and pharmacological profile of selective adenosine receptor agonists 202
Evaluation of adenine as scaffold for the development of novel P2X3 receptor antagonists 202
GPCRs as therapeutic targets: a view on adenosine receptors structure and functions, and molecular modeling support 199
A(2B) adenosine receptor agonists: synthesis and biological evaluation of 2-phenylhydroxypropynyladenosine and NECA derivatives 199
Well water in central Italy: Analysis of herbicide residues as potential pollutants of untreated crops 198
Purine and 1-deazapurine ribonucleosides and deoxyribonucleosides: synthesis and biological activity 198
Functional cAMP assay optimization at CHO cells expressing A2A adenosine receptors and stably transfected with firefly luciferase biosensor 198
Exploring the 2- and 5-positions of the pyrazolo[4,3-d]pyrimidin-7-amino scaffold to target human A1 and A2A adenosine receptors 198
A2A Adenosine Receptor Antagonists: Are Triazolotriazine and Purine Scaffolds Interchangeable? 197
Adenosine deaminase inhibitors: synthesis, diastereoisomeric resolution and biological activity of 1-(2-hydroxy-3-nonyl)-1,2,4-triazole-3-carboxamide 196
9-Ethyladenine derivatives as adenosine receptor antagonists: 2- and 8-substitution result in distinct selectivities. 196
Totale 25.814
Salva come PNG Salva come JPEG
Categoria #
all - tutte 158.637
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 158.637
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.406 0 0 0 91 122 119 102 167 170 235 157 243
2022/20232.525 256 144 76 420 277 361 11 154 461 134 165 66
2023/20241.883 265 100 110 76 87 173 87 104 222 62 49 548
2024/20256.213 231 140 527 295 200 361 709 1.540 518 436 382 874
2025/20269.009 538 524 1.072 1.240 984 701 1.487 581 511 580 482 309
2026/20272.937 612 308 698 1.319 0 0 0 0 0 0 0 0
Totale 40.234